

**THE EXPRESSION OF INSULIN-LIKE GROWTH FACTORS AND THEIR
RECEPTORS AT PREIMPLANTATION STAGE IN REPRODUCTIVE TISSUE
OF DIABETIC MOUSE**

RAHIMAH BINTI ZAKARIA

UNIVERSITI SAINS MALAYSIA

2007

**THE EXPRESSION OF INSULIN-LIKE GROWTH FACTORS AND THEIR
RECEPTORS AT PREIMPLANTATION STAGE IN REPRODUCTIVE TISSUE
OF DIABETIC MOUSE**

by

RAHIMAH BINTI ZAKARIA

**Thesis submitted in fulfilment of the
requirements for the degree of
Doctor of Philosophy**

NOVEMBER 2006

ACKNOWLEDGEMENTS

In the name of Allah, the Most Merciful and the Most Compassionate

I would like to express my deepest gratitude and indebtedness thanks to my supervisors, Associate Professor (Dr) Nik Soriani Yaacob and Professor (Dr) Norazmi Mohd Nor for their fine and dedicated supervision throughout my studies and their thorough criticisms during my thesis writing. I am also thankful to my field supervisor, Professor (Dr) Mohd Hamim Rajikin for his encouragement and criticisms throughout my study until I completed my thesis writing. I would like to thank Professor (Dr) Harbindar Jeet Professor, Head of Department of Physiology, for his support during my study.

My thanks to our Dean of School of Medical Sciences, Professor (Dr) Abdul Aziz Baba, and Deputy Deans of School of Medical Sciences for their encouragement throughout my studies.

I would like to thank Professor (Dr) Asma Ismail, Director of INFORMM and Professor (Dr) Zainul Fadziruddin Zainuddin, Dean of School of Health Sciences for giving me the opportunity to work in their laboratories. My thanks to staff of Department of Physiology (USM and UKM, Kuala Lumpur), Animal House, Department of Pathology, INFORMM and School of Health Sciences for their kind assistance.

My special thanks to my dearest friend, Dr Asma Hayati Ahmad, for her encouragement during my study and her criticisms during my thesis writing. To all my friends in the department, Dr Mahaneem, Dr Che Badariah, Dr Wan Malihah, Dr Liza and Dr Adibah, and also my research group members, Mar, Ima, Teo, Asma, Rafezul, Dr Zul, Syam and Ayu, thank you to all of them for their assistance and support.

Finally to both my parents, my husband, my sons, Haikal, Haziq and Hadif, my sisters and brother, a very special thanks to all of them for their love, understanding and encouragement which allow me to complete my studies and thesis writing.

I would like to acknowledge Ministry of Science and Technology for financially support this research work via Fundamental Research Grant Scheme (FRGS).

TABLE OF CONTENTS

	Page	
ACKNOWLEDGEMENTS	ii	
TABLE OF CONTENTS	iv	
LIST OF TABLES	xi	
LIST OF FIGURES	xiii	
LIST OF PLATES	xvi	
LIST OF ABBREVIATIONS	xviii	
ABSTRAK	xxiii	
ABSTRACT	xxv	
CHAPTER ONE : GENERAL INTRODUCTION		
1.1	Physiology of preimplantation embryo development	1
	1.1.1 Proliferation and differentiation of preimplantation embryo	1
	1.1.2 Metabolic activity of preimplantation embryo	3
	1.1.3 Influence of maternal factors on preimplantation embryo development	4
1.2	Diabetic pregnancy	5
1.3	Definition of the term “diabetic embryopathy”	8
1.4	Aetiological factors associated with diabetic embryopathy	8
	1.4.1 Maternal Hyperglycemia	9
	1.4.2 Maternal Hyperketonemia	15
	1.4.3 Maternal Hypoglycemia	16
	1.4.4 Free Oxygen Radicals	16

1.4.5	Genetic Susceptibility	18
1.4.6	Other Maternal Factors	20
1.5	Fuel-mediated teratogenesis	21
1.6	Insulin-like growth factors (IGFs)	22
1.7	Insulin-like growth factor-1 (IGF-1)	23
1.7.1	IGF-1 gene	24
1.7.2	Biosynthesis of IGF-1	26
1.8	Insulin-like growth factor-2 (IGF-2)	27
1.8.1	IGF-2 gene	27
1.8.2	Biosynthesis of IGF-2	29
1.9	Biological actions of IGFs	29
1.9.1	Effects of IGF-1 administration to humans	32
1.9.2	Effects of IGF-1 administration to animals	32
1.9.3	Effects of IGF-1 overexpression in transgenic animals	35
1.9.4	Effects of IGFs and IGFs receptor null mutations	35
1.10	Regulations of IGFs expression	35
1.11	Insulin-like growth factor-1 receptor (IGF-1R)	40
1.12	IGF-1R signaling pathways	43
1.12.1	Signalling via the MAPK pathway	45
1.12.2	Signalling via the PI-3K - Akt pathway	47
1.13	Insulin-like growth factor-2 receptor (IGF-2R)	48
1.13.1	IGF-2R signalling pathways	49
1.14	IGFs receptor distribution	49
1.15	Insulin-like growth factor binding proteins (IGFBP)	50
1.15.1	Structure of IGFBP	50

1.15.2	IGFBP gene	53
1.15.3	Biosynthesis of IGFBP	53
1.15.4	Actions of IGFBP	54
1.15.5	Modulation of IGFs action by IGFBP	54
1.16	Real-time polymerase chain reaction (PCR)	56
1.16.1	DNA-binding dyes	56
1.16.2	Molecular beacons	58
1.16.3	Hybridisation probes	60
1.16.4	Hydrolysis probes	61
1.17	Research objectives and justification	65
CHAPTER TWO : MATERIALS AND METHODS		
2.1	Materials	67
2.2	Preparation of solutions, buffers and media	67
2.2.1	Ammonia	67
2.2.2	Ampicillin stock solution (50 mg/ml)	67
2.2.3	Calcium chloride (CaCl ₂) solution (0.1 M)	73
2.2.4	DAB (3, 3'-diaminobenzidine tetrahydrochloride)	73
2.2.5	Diethylpyrocarbonate (DEPC)-treated water (0.1%)	73
2.2.6	DNA molecular size markers	73
2.2.7	Ethanol (95%)	73
2.2.8	Ethanol (80%)	74
2.2.9	Ethanol (70%)	74
2.2.10	Ethanol (50%)	74
2.2.11	Ethidium bromide (EtBr) solution (10 mg/ml)	74
2.2.12	Ethylenediamine-tetra acetic acid (EDTA) solution (0.5 M)	74

2.2.13	Formal saline (10%)	75
2.2.14	Glycerol solution (80%)	75
2.2.15	Hepes Buffered Whitten's medium	75
2.2.16	Human Chorionic Gonadotropin (hCG)	75
2.2.17	Hydrochloric acid (HCl) solution (1 M)	76
2.2.18	Hydrogen peroxide (H ₂ O ₂ , 3%)	76
2.2.19	Kanamycin stock solution (50 mg/ml)	76
2.2.20	Loading buffer for agarose gel electrophoresis	76
2.2.21	Luria-Bertani (LB) agar	76
2.2.22	Luria-Bertani (LB) broth	77
2.2.23	Magnesium chloride (MgCl ₂) solution (0.1 M)	77
2.2.24	Phosphate-buffered saline (PBS)	77
2.2.25	Pregnant Mare Serum Gonadotropin (PMSG)	77
2.2.26	Sodium-dodecyl sulphate (SDS) solution (10%)	78
2.2.27	Sodium EDTA (10 mM)	78
2.2.28	Sodium hydroxide (NaOH) solution (3 M)	78
2.2.29	Tris-Borate-EDTA (TBE) buffer (10 x)	78
2.2.30	Tris-EDTA buffer, pH 9.0	79
2.2.31	Whitten's medium	79
2.2.32	X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) stock (40 mg/ml)	79
2.3	Animal preparation and tissue collection	80
2.3.1	Diabetic induction	80
2.3.2	Superovulation and mating	80
2.3.3	Tissue collection	82

2.3.4	Collection and culture of preimplantation embryos	83
2.4	Total RNA extraction	85
2.5	Determination of RNA yield, purity and integrity	86
2.6	First strand cDNA synthesis	86
2.7	Polymerase chain reaction (PCR)	88
2.7.1	Preparation of PCR master mix	88
2.7.2	Assembly PCR	88
2.7.3	Preparation of agarose gel for electrophoresis	88
2.7.4	Fractionation of samples on agarose gel electrophoresis	89
2.8	Cloning	91
2.8.1	Preparation of TOP 10 <i>E.coli</i> competent cells	91
2.8.2	PCR A tailing	92
2.8.3	Transformation into TOP 10 <i>E. coli</i> competent cells	93
2.8.4	Screening of positive colonies	93
2.9	Plasmid extraction	94
2.10	Verification of the PCR insert	95
2.11	Real-time PCR	96
2.11.1	Designing primers and probes	96
2.11.2	Preparation of PCR primer working solution	97
2.11.3	Preparation of probe working solution	98
2.11.4	Preparation of Real-time PCR mixture	98
2.11.5	Real-time PCR thermal profile	100
2.12	Immunohistochemistry	100
2.12.1	Tissue processing	100
2.12.2	Preparation of tissue sections	100

2.12.3	Antibody dilution, incubation time and temperature	100
2.13.4	Immunohistochemical staining	101
2.13	Statistical analyses	103
CHAPTER THREE: THE EFFECT OF DIABETES MELLITUS ON <i>IN VITRO</i> DEVELOPMENT OF MOUSE PREIMPLANTATION EMBRYO		
3.1	Introduction	104
3.2	Results	105
3.3	Discussion	106
CHAPTER FOUR : QUANTIFICATION OF mRNA EXPRESSION OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS IN THE FALLOPIAN TUBES AND UTERI OF DIABETIC MICE DURING PREIMPLANTATION EMBRYO DEVELOPMENT		
4.1	Introduction	113
4.2	Development of homologous internal standards for Real-time PCR	114
4.2.1	Generation of synthetic IGF-1, IGF-2, IGF-1R and IGF-2R genes	116
4.2.2	Cloning into pCR 2.1 TOPO cloning vector	116
4.2.3	Preliminary Real-time PCR runs	120
4.3	Real-time quantification of mRNA expression of IGFs and their receptors	124
4.3.1	Primers and probes	124
4.3.2	Total RNA yield, purity and integrity	126
4.3.3	First strand cDNA synthesis	126
4.3.4	Real-time PCR analysis	136
4.3.5	Expression of IGFs and their receptors gene	136

4.4	Discussion	142
CHAPTER FIVE : IMMUNOHISTOCHEMICAL DETECTION AND LOCALIZATION OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS IN THE FALLOPIAN TUBES AND UTERI OF DIABETIC MICE DURING PREIMPLANTATION EMBRYO DEVELOPMENT		
5.1	Introduction	148
5.2	Optimization of antibody dilution, incubation time and temperature	149
5.3	Distribution of IGFs and their receptors in the mouse fallopian tube and uterus	152
5.4	Immunohistochemical scoring	152
5.4.1	Median score of IGFs and their receptors in the mouse fallopian tube	156
5.34.2	Median score of IGFs and their receptors in the mouse uterus	166
5.5	Discussion	166
CHAPTER SIX : GENERAL DISCUSSION		
6.1	Overall discussion	170
6.2	Study limitation and future study	180
CHAPTER SEVEN : SUMMARY AND CONCLUSION		183
BIBLIOGRAPHY		186
APPENDICES		
Appendix A: Animal Ethics Committee Universiti Sains Malaysia		
LIST OF PUBLICATIONS		

LIST OF TABLES

	Page
1.1 Congenital malformations in infants of diabetic mothers	7
1.2 The effects of IGF-1 administration to humans	33
1.3 The effect of IGF-1 overexpression in transgenic mice	36
1.4 The effects of IGFs and IGFs receptor null mutations	37
1.5 The binding affinity between insulin, IGFs and their receptors	44
1.6 Affinities of IGFBP for IGF-1 and -2	51
2.1 List of chemicals and reagents	68
2.2 List of commercial kits and consumables	70
2.3 List of laboratory equipments	71
2.4 List of antibodies	72
2.5 Mobility range of DNA in different percentage agarose gels	90
2.6 The composition of a Real-time PCR mixture	99
3.1 The effect of diabetes on two-cell embryo development in control and diabetic mice	108
4.1 The oligonucleotide sequences of IGF-1, IGF-2, IGF-1R and IGF-2R	117
4.2 Optimum PCR conditions and thermal profiles for development of homologous internal standards	118
4.3 The characteristics of primers and probe designed for mouse IGF-1	131

4.4	The characteristics of primers and probe designed for mouse IGF-2	132
4.5	The characteristics of primers and probe designed for mouse IGF-1R	133
4.6	The characteristics of primers and probe designed for mouse IGF-2R	134
5.1	Summary of primary and secondary antibodies	150
5.2	Immunohistochemical scoring for IGF-1, IGF-2, IGF-1R and IGF-2R in the fallopian tube of control and diabetic mice	161
5.3	Immunohistochemical scoring for IGF-1, IGF-2, IGF-1R and IGF-2R in the uterus of control and diabetic mice	167

LIST OF FIGURES

	Page
1.1 Development of the preimplantation embryo in mice from embryonic Day 1 through Day 4	2
1.2 A theoretical model summarizing the physiological processes that influence the microenvironment of the preimplantation embryo	6
1.3 Mechanism of hyperglycemia-induced alterations in cell division and congenital anomalies	12
1.4 Potential molecular pathways involved in diabetic embryopathy	19
1.5 Structures of IGF-1 and -2 genes	25
1.6 Structures of IGF-1R and IGF-2R	42
1.7 Signalling pathways activated by IGF-1R	46
1.8 DNA-binding dyes	57
1.9 Molecular beacons	59
1.10 Hybridisation probes	62
1.11 Hydrolysis probes	64
2.1 A workflow chart for animal preparation and tissue collection	81
2.2 A workflow chart for animal preparation and embryo culture experiment	84
4.1 A workflow chart for the development of homologous internal standards	115

4.2	The assembly PCR products for the generation of synthetic IGF-1, IGF-2, IGF-1R and IGF-2R genes	119
4.3	Screening for positive clones of IGF-1, IGF-2 and IGF-2R by PCR	121
4.4	Screening for positive clones of IGF-1R by PCR	122
4.5	Example of an amplification plot in delta Rn versus number of cycles and a standard curve for the quantification of the homologous internal standards for IGF-2	123
4.6	A workflow chart for the Real-time quantification of mRNA expression	125
4.7	The full mRNA sequence of mouse IGF-1 and the location of the primers and probes designed	127
4.8	The full mRNA sequence of mouse IGF-2 and the location of the primers and probes designed	128
4.9	The mRNA sequence of mouse IGF-1R and the location of the primers and probes designed	129
4.10	The mRNA sequence of mouse IGF-2R and the location of the primers and probes designed	130
4.11	Verification of the total RNA integrity	135
4.12	Verification of the success of the first strand cDNA synthesis	137
4.13	mRNA expression of IGF-1 in the fallopian tube and uterus of control and diabetic mice	139
4.14	mRNA expression of IGF-2 in the fallopian tube and uterus of control and diabetic mice	140
4.15	mRNA expression of IGF-1R in the fallopian tube and uterus of control and diabetic mice	141

4.16	mRNA expression of IGF-2R in the fallopian tube and uterus of control and diabetic mice	143
6.1	Hypothetical mechanism of diabetic embryopathy	173

LIST OF PLATES

	Page
3.1	107
Photographs showing normal mouse embryos (A) at 0 hour (B) after 24 hours (C) after 48 hours (D) after 72 hours <i>in vitro</i> culture	
3.2	109
Photographs showing degenerated mouse embryos obtained from diabetic mice after 72 hours <i>in vitro</i> culture	
5.1	151
Positive tissue controls	
5.2	153
Negative control using normal rabbit serum IgG	
5.3	154
Immunostaining for IGFs and their receptors in the mouse fallopian tube	
5.4	155
Immunostaining for IGFs and their receptors in the mouse uterus	
5.5	157
Immunostaining for IGF-1 in mouse uterus (A) Score 0, (B) Score 1, (C) Score 2, (D) Score 3 and (E) Score 4	
5.6	158
Immunostaining for IGF-2 in mouse uterus (A) Score 0, (B) Score 1, (C) Score 2, (D) Score 3 and (E) Score 4	
5.7	159
Immunostaining for IGF-1R in mouse uterus (A) Score 0, (B) Score 1, (C) Score 2, (D) Score 3 and (E) Score 4	
5.8	160
Immunostaining for IGF-2R in mouse uterus (A) Score 0, (B) Score 1, (C) Score 2, (D) Score 3 and (E) Score 4	
5.9	162
Examples of immunohistochemical scoring for IGF-1 in the fallopian tubes of control and diabetic mice	

- 5.10 Examples of immunohistochemical scoring for IGF-2 in the fallopian tubes of control and diabetic mice 163
- 5.11 Examples of immunohistochemical scoring for IGF-1R in the fallopian tubes of control and diabetic mice 164
- 5.12 Examples of immunohistochemical scoring for IGF-2R in the fallopian tubes of control and diabetic mice 165

LIST OF ABBREVIATIONS

AA	arachidonic acid
ACTH	adrenocorticotropic hormone
AGE	advanced glycation end products
Akt	protein kinase B
ALS	acid-labile subunit
ATP	adenosine triphosphate
BAD	Bcl-xL/Bcl-2-associated death protein
BSA	Bovine Serum Albumin
CaCl ₂	calcium chloride
cDNA	complementary DNA
cds	coding region
COX-2	cyclooxygenase-2
C-peptide	connecting peptide
cPLA ₂	cytosolic phospholipase A ₂
CRK	CT10 regulator of kinase
C _T	threshold cycle
Da	Dalton
DAB	3, 3'-diaminobenzidine tetrahydrochloride
DEPC	diethylpyrocarbonate

DHA	dehydroascorbate
DNA	deoxyribonucleic acid
DPX	distyrene plasticiser xylene
ECM	extracellular matrix
EDTA	ethylenediamine-tetra acetic acid
ER α	oestrogen receptor- α
ERK	extracellular signal-related kinase
EtBr	ethidium bromide
FBP	fructose 1,6-biphosphate
FGF	fibroblast growth factor
FSH	follicle stimulating hormone
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GDP	guanine diphosphate
GH	growth hormone
GLUT	glucose transporters
Grb	growth factor receptor-bound protein
GTP	guanine triphosphate
H & E	hematoxylin and eosin
H ₂ O ₂	hydrogen peroxide
hCG	Human Chorionic Gonadotropin
HCl	hydrochloric acid
HIF-1 α	hypoxia-inducible factor 1 α
HPRT	hypoxanthine phosphoribosyltransferase
ICM	inner cell mass
ICR	Institute of Cancer Research

IGF-1	insulin-like growth factor-1
IGF-1R	IGF-1 receptor
IGF-2	insulin-like growth factor-2
IGF-2R	IGF-2 receptor
IGFBP	IGFs binding proteins
IGFBP-rPs	IGFBP-related proteins
IGFs	insulin-like growth factors
IgG	Immunoglobulin G
IHC	immunohistochemistry
IL-1 β	interleukin-1 β
IP3	inositol triphosphate
IR	insulin receptor
IRS	insulin-receptor substrate
JNK	c-Jun N-terminal kinase
kb	kilobase
kDa	kiloDalton
LB	Luria-Bertani
LH	luteinizing hormone
M6P	mannose-6-phosphate
MAPK	mitogen-activated protein kinase
MEK	MAP/ERK kinases
MEKK	MEK kinase
MgCl ₂	magnesium chloride
mRNA	messenger ribonucleic acid
MSA	multiplication-stimulating activity

mSOS	Son of sevenless
NaOH	sodium hydroxide
NCBI	National Center For Biotechnology Information
NIH	National Institute of Health
NOD	non-obese diabetic
NSILA	non-suppressible insulin-like activity in serum
NTC	no template control
PBS	phosphate-buffered saline
PCR	Polymerase Chain Reaction
PDGF	platelet-derived growth factor
PDK	3-phosphoinositide dependent kinases
PGE ₂	prostaglandin E ₂
PGF ₂	prostaglandin F ₂
PH	plekstrin homology
PI	phosphoinositides
PI-3K	phosphatidylinositol-3 kinase
PIP	phosphatidylinositol phosphate
PIP ₂	phosphatidylinositol bisphosphate
PKB	protein kinase B
PKC	protein kinase C
PMSG	Pregnant Mare Serum Gonadotropin
PTB	phosphotyrosine binding
R ²	square regression coefficient value
RNA	ribonucleic acid
ROS	reactive oxygen species

SAPK	stress-activated protein kinase
SDS	sodium-dodecyl sulphate
SFA	sulfation factor activity
SH	Src-homology
SHC	Src homology-containing protein
SOC	sodium citrate medium
SOD	superoxide dismutase
STZ	streptozotocin
TBE	Tris-Borate-EDTA
TCA	tricarboxylic acid
TE	trophectoderm
TGF- β	transforming growth factor- β
T _m	melting temperature
TNF- α	tumour necrosis factor- α
TSH	thyrotropin
UNG	uracyl-N-glycosylase
X-gal	5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside

EKSPRESI "INSULIN-LIKE GROWTH FACTORS" DAN RESEPTORNYA PADA PERINGKAT PRAIMPLANTASI DALAM TISU REPRODUKTIF MENCIT DIABETES

ABSTRAK

Kami menghipotesis bahawa embrio praimplantasi yang berkembang dalam persekitaran diabetes mengalami kekurangan faktor pertumbuhan tertentu. Tujuan utama kajian ini adalah untuk menentukan kesan diabetes ke atas perkembangan embrio praimplantasi mencit secara *in vitro* dan menganalisis ekspresi mRNA dan protein IGF-1, IGF-2, IGF-1R dan IGF-2R dalam tisu fallopio dan uterus mencit kontrol dan diabetes. Mencit ICR betina yang matang secara seksual berusia 6 hingga 8 minggu dijadikan diabetes dengan suntikan streptozotosin (200 mg/kg, intra peritoneum). Embrio normal dalam peringkat 2-sel diperolehi daripada mencit kontrol dan diabetes yang disuperovulasi pada 48 jam pasca rawatan korionik gonadotropin manusia (hCG). Embrio dikultur secara berasingan dan diperiksa di bawah mikroskop songsang selama 3 hari berturut-turut. Tisu fallopio dan uterus diperolehi daripada mencit kontrol dan diabetes yang disuperovulasi pada 48, 72 dan 96 jam pasca rawatan hCG. Kuantifikasi ekspresi mRNA menggunakan tindak balas polimerase masa nyata menggunakan piawai internal homologus yang dibangunkan secara spesifik untuk setiap gen. Ekspresi protein menggunakan pewarnaan imunohistokimia dijalankan ke atas tisu dan skor semikuantitatif dibuat berdasarkan sistem 5-skala piawai. Bilangan embrio 2-sel yang diperolehi daripada mencit diabetes

adalah sangat berkurangan apabila dibanding dengan mencit kontrol. Walau bagaimanapun, tiada perbezaan yang signifikan dalam peratus perkembangan embrio 2-sel mencit kontrol dan diabetes. Ekspresi mRNA IGF-1 tisu fallopio dan uterus mencit diabetes rendah secara signifikan masing-masing pada 72 dan 96 jam pasca rawatan hCG. Ekspresi mRNA IGF-1R kekal tinggi dalam tisu fallopio tetapi rendah secara signifikan dalam tisu uterus mencit diabetes pada 96 jam pasca rawatan hCG. Ekspresi mRNA IGF-2 tisu fallopio mencit diabetes tinggi secara signifikan pada 48 dan 96 jam pasca rawatan hCG tetapi rendah secara signifikan dalam tisu uterus mencit diabetes pada 96 jam pasca rawatan hCG. Ekspresi mRNA IGF-2R tisu fallopio dan uterus mencit diabetes tinggi secara signifikan masing-masing pada 48 dan 96 jam, dan 48 jam pasca rawatan hCG. Untuk ekspresi protein, skor imunohistokimia IGF-1 dan IGF-1R berkurang secara signifikan dalam tisu fallopio pada 96 jam pasca rawatan hCG. Skor IGF-2 dan IGF-2R sebaliknya bertambah secara signifikan dalam tisu fallopio mencit diabetes masing-masing pada 48 dan 72 jam, dan pada 72 jam pasca rawatan hCG. Walau bagaimanapun, tiada perbezaan skor yang signifikan bagi IGFs dan reseptornya dalam tisu uterus mencit kontrol dan diabetes. Sebagai kesimpulan, peratus perkembangan embrio 2-sel kepada blastosista adalah serupa di dalam mencit kontrol dan diabetes tetapi tidak dapat disahkan sama ada kualiti embrio tersebut sama atau tidak. Ekspresi mRNA dan protein IGFs dan reseptor masing-masing mengalami perubahan yang signifikan akibat kesan diabetes ibu, mencadangkan wujudnya peranan mereka dalam patogenesis embriopati diabetes.

THE EXPRESSION OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS AT PREIMPLANTATION STAGE IN REPRODUCTIVE TISSUES OF DIABETIC MOUSE

ABSTRACT

We hypothesized that the alteration in the expression of IGFs and their receptors may create an abnormal intrauterine environment thus affect embryos development. Therefore, the aims of the present study were to determine the effects of diabetes on *in vitro* development of mouse preimplantation embryos and to determine the mRNA and protein expression of IGF-1, IGF-2, IGF-1R and IGF-2R in the fallopian tube and uterine tissue of control and diabetic mice. Sexually mature female ICR mice of 6-8 weeks old were made diabetic by streptozotocin (200 mg/kg, intraperitoneal). The normal two-cell embryos were obtained from superovulated control and diabetic mice at 48 post-hCG treatment. Embryos were separately cultured and examined under an inverted microscope for 3 consecutive days. Fallopian tubes and uterine tissues were obtained from the superovulated control and diabetic mice at 48, 72 and 96 hours post-hCG treatment. The mRNA expression was measured using Real-time PCR using specifically developed homologous internal standards for each gene. Protein expression was measured by immunohistochemical staining and a semiquantitative scoring was performed using a standardized 5-scale system. The number of normal two-cell embryos obtained from diabetic mice was much reduced when compared to control mice. However, there was no significant

difference in the percentage of two-cell embryo development in control and diabetic mice. The mRNA expression of IGF-1 in the fallopian tube and uterus of diabetic mice was significantly low at 72 hours and 96 hours post-hCG treatment, respectively. The mRNA expression of IGF-1R remained high in the fallopian tube but was significantly low in the uterus of diabetic mice at 96 hours post-hCG treatment. The mRNA expression IGF-2 in the fallopian tube was significantly high at 48 and 96 hours post-hCG treatment but was significantly low in the uterus of diabetic mice at 96 hours post-hCG treatment. The mRNA expression of IGF-2R in the fallopian tube and uterus of diabetic mice was significantly high at 48 and 96 hours, and at 48 hours post-hCG treatments, respectively. For protein expression, the immunohistochemical scoring for both IGF-1 and IGF-1R was significantly decreased in the fallopian tube of diabetic mice at 96 hours post-hCG treatment. In contrast, the score for IGF-2 and IGF-2R was significantly increased in the fallopian tube of diabetic mice at 48 and 72 hours; and at 72 hours post-hCG treatment, respectively. However, there was no significant difference in the score of IGFs and their receptors in the uterus of control and diabetic mice. In conclusion, the percentage of the two-cell stage embryos which developed to blastocysts was similar in control and diabetic groups but whether the quality of these embryos were the same could not be confirmed. Both the mRNA and protein expression of IGFs and their receptors were significantly altered by maternal diabetes, which suggest their role in the pathogenesis of diabetic embryopathy.

CHAPTER ONE

GENERAL INTRODUCTION

1.1 PHYSIOLOGY OF PREIMPLANTATION EMBRYO DEVELOPMENT

1.1.1 Proliferation and differentiation of preimplantation embryo

Fertilization of the mouse ovum by sperm occurs in the ampullary region of the fallopian tube. Subsequent development occurs as the embryo moves down the fallopian tube and into the uterus over a period of about four days in mice, as compared to five and seven days in rats and humans, respectively (Figure 1.1). Approximately 24 hours after fertilization, the embryo undergoes relatively synchronous cell division resulting in the formation of two cells or blastomers. There are no junctions established between the individual cells, which are held together by ionic attractions on the opposing plasma membranes (Chavez, 1984). The cells are constrained within a physical shell, the zona pellucida, which is a matrix of four glycoproteins (Wassarman and Mortillo, 1991). During this period, each blastomere is totipotent, retaining the capacity to form a complete fetus. Further mitotic divisions occur asynchronously at progressively shorter intervals so that from the eight-cell stage onwards, one cell cycle is approximately six hours. At the eight-cell stage, generation of two distinct lineages commences with the process of compaction when individual blastomers polarize, become epithelial-like and flatten on each other,




Figure 1.1 Development of the preimplantation embryo in mice from embryonic Day 1 through Day 4

(Adapted from Hogan *et al.*, 1986)

The fertilization takes place in the ampullary region of the fallopian tube and the developing embryo traverse down to the site of implantation in the uterine cavity.

maximising cell contact and forming tight and gap junctions (Ducibella *et al.*, 1977; Magnuson and Epstein, 1981; Chavez, 1984; Fleming *et al.*, 1992). This compacted morula stage coincides with the arrival of the embryo at the utero-tubal junction. In the compacted morula, fluid is transported across the newly formed epithelium to form a blastocoel and at this point the embryo is referred to as a blastocyst. At this stage, two distinct cell populations can be recognized (Johnson, 1981). The eccentrically placed inner cell mass (ICM) eventually forms the embryo proper and some extraembryonic tissues. The trophectoderm (TE), which is a single epithelial layer of flattened cells surrounding the blastocoel and ICM, establishes the foci of adhesion with the uterine epithelium and gives rise to the fetal component of the placenta (Hogan *et al.*, 1986).

1.1.2 Metabolic activity of preimplantation embryo

Mouse oocyte and zygote have an absolute requirement for pyruvate (Biggers *et al.*, 1967); i.e. glucose cannot support early embryo development until the eight-cell stage (Biggers, 1971). From the two-cell to the blastocyst stage, the embryos experience an increase in the tricarboxylic acid (TCA) cycle metabolites and a dramatic increase in fructose 1, 6-biphosphate (FBP). The dramatic switch from a dependence on the TCA to a metabolism based on glycolysis occurs at the time of compaction. The only source of adenosine triphosphate (ATP) for the preimplantation embryo would be conversion of glucose to pyruvate and lactate via glycolysis.

The blastocyst stage marks a new peak in cellular proliferation and growth. These changes create new biosynthetic demands on the embryos.

Maintenance of a high rate of glycolysis is important for providing a “dynamic buffer” of metabolic intermediates for the biosynthesis of macromolecules (Newsholme and Newsholme, 1989) and increasing amount of glucose are converted to lactate at this stage in humans and rodents (Leese and Barton, 1984). Interspecies variations in the rate of glycolysis have been reported, higher in human blastocysts (Leese *et al.*, 1993) and lower in mouse blastocysts (Leese, 1991) compared to rat embryos.

Blastocysts are actively engaged in the uptake and metabolism of maternally derived nutrients such as glucose (Leese, 1991). The major site of uptake regulation is likely to be the system of facilitative glucose transporters (GLUT) situated at the basolateral surface of the TE in mouse blastocysts (Aghayan *et al.*, 1992).

1.1.3 Influence of maternal factors on preimplantation embryo development

Although the activation of the embryonic genome provides the conceptus with a number of vital developmental signals (Kidder, 1992; Schultz and Heyner, 1992), its progression through the preimplantation period is also influenced by maternal factors present in the oviductal and uterine environment.

Biggers (1981) proposed a theoretical model summarizing the physiological processes that influence the microenvironment of the preimplantation embryo. The composition of the microenvironment is determined by several transport mechanisms: between the embryo and the

secretions in which it is bathed, between the fallopian tube and uterus and the bathing secretions and further mixing is produced as the secretions flow up and down the reproductive tract as shown in Figure 1.2.

Maternally-derived nutrients/factors can either be transudates from the maternal circulation such as glucose (Leese *et al.*, 1979, Wales and Edirisinghe, 1989; Gonzalez *et al.*, 1994) and insulin (Heyner *et al.*, 1989; Smith *et al.*, 1993), or secretions by various uterine cells into the lumen such as growth factors (Pollard, 1990; Song *et al.*, 2000) and cytokines (Pampfer *et al.*, 1991; Robertson *et al.*, 2001) during the preimplantation period.

1.2 DIABETIC PREGNANCY

The association between maternal diabetes and the increased risk of congenital malformations has a long history and was first reported by LeCorche (1885). It is generally accepted that congenital malformations are the leading cause of death in the offspring of diabetic women (Kitzmilller *et al.*, 1978). The incidence of congenital malformations is approximately 6 to 9% in diabetic pregnancies, which is three- to four-fold higher than in the general population, and accounts for 33 to 66% of perinatal deaths (Reece and Hobbins, 1986). The congenital malformations most commonly associated with maternal diabetes are listed in Table 1.1 (Reece and Hobbins, 1986). However, none of the reported congenital malformations is pathognomonic for the diagnosis of diabetic embryopathy.




Figure 1.2 A theoretical model summarising the physiological processes that influence the microenvironment of the preimplantation embryo (Adapted from Biggers, 1981).

1.3 DEFINITION OF “DIABETIC EMBRYOPATHY”

The term “embryopathia diabetica” was coined by Mayer (1952) and was later replaced by the term “diabetic embryopathy” (Passarge and Lenz, 1966). The concept of diabetic embryopathy initially encompassed the long-recognized newborn features such as macrosomia and organomegaly but was later broadened to include congenital malformations (Mayer and Camara, 1964). Presently, the same concept was separated into two different entities, diabetic embryopathy and diabetic fetopathy. Diabetic embryopathy occurs during embryogenesis, mainly from the end of blastogenesis until the period of organogenesis (between the 3rd and 7th week of gestation) and is associated with congenital malformations (Kousseff, 1999). In contrast, diabetic fetopathy occurs during fetal development, after the 10th week of gestation, and is not associated with malformations (Kousseff, 1999). Occasionally, diabetic embryopathy is associated with diabetic fetopathy. However, these two entities, both induced by maternal diabetes mellitus, have different windows of vulnerability and perhaps, different pathogenesis.

1.4 AETIOLOGICAL FACTORS ASSOCIATED WITH DIABETIC EMBRYOPATHY

It has been suggested that the absence of a specific malformation pattern for diabetic embryopathy signals the presence of several aetiological factors and mechanisms in diabetic pregnancy (Khoury *et al.*, 1989). Likewise, the number of different teratogenic agents identified indicates that diabetic embryopathy is of complex aetiology (Sadler *et al.*, 1989; Zusman *et al.*, 1989; Buchanan *et al.*, 1994).

1.4.1 Maternal Hyperglycemia

Hyperglycemia-induced teratogenic effects have been demonstrated in animal studies both *in vivo* and *in vitro* (Cockroft and Coppola, 1977; Baker *et al.*, 1981; Horton and Sadler, 1983; Kalter and Warkany, 1983a & 1983b; Freinkel *et al.*, 1986; Reece and Hobbins, 1986). The percentage of congenital malformations correlated with blood glucose levels (Reece *et al.*, 1985) and glycosylated hemoglobin levels (Rose *et al.*, 1988).

The period and time of exposure to hyperglycemia as well as the level of hyperglycemia are all important for dysmorphogenesis to occur. The critical period of exposure to hyperglycemia is during organogenesis, which is considered to be between days 9.5 to 11.5 in rats and 8.0 to 9.6 in mice (Freinkel, 1988), corresponding to the first 5 or 6 weeks of human pregnancy. A minimum exposure time of two or more hours is needed to induce these malformations. A 20% malformation rate was induced at glucose levels that were approximately two-fold above normal concentrations; an almost 50% malformation rate was seen at glucose levels three-fold above normal concentrations; and approximately 100% rate at six times above normal concentrations (Reece *et al.*, 1985).

Maternal hyperglycemia adversely affects not only the postimplantation embryos but also preimplantation progression from one-cell to the blastocyst stage in a streptozotocin (STZ)-induced or a non-obese diabetic (NOD) mouse model (Diamond *et al.*, 1989; Moley *et al.*, 1991 & 1994). In the NOD model at 96 hours after superovulation and mating, only 20% of the recovered embryos

reached blastocyst stage in the diabetic compared to 90% among the non-diabetic. This developmental delay is reversible by treating the mothers with insulin before superovulation and mating and during the first 96 hours of gestation. This early preimplantation delay may be manifested later in gestation as fetal loss, early growth delay or congenital malformation. There is now convincing evidence that severe developmental anomalies leading to fetal resorption or malformation can occur as a consequence of subtle damage inflicted to the embryos before or at the time of implantation (Rutledge, 1997).

The mechanism of hyperglycemia-induced congenital anomalies remains unclear. Hyperglycemia-induced reduction in GLUT has been proposed to be one of the possible mechanisms. A paradoxical reaction to hyperglycemia has been demonstrated in preimplantation embryos (Moley, 1999). In embryos of diabetic mice, a pronounced intracellular hypoglycemia was found despite maternal hyperglycemia (Moley *et al.*, 1998b). The decreased intracellular glucose concentration was associated with decreased GLUT namely, GLUT-1, GLUT-2 and GLUT-3 isoforms; both at the protein and mRNA levels (Moley *et al.*, 1998b).

Reduced availability of glucose associated with decreased GLUT in diabetic embryos, results in significantly lower FBP and higher pyruvate, indicating decreased glycolysis and increased pyruvate uptake by the embryos, respectively. The glycolytic changes lead to dysfunction of the outer mitochondrial membrane and subsequently trigger the apoptotic cascade (Chi *et al.*, 2002).

The decrease in GLUT especially GLUT-1 and -3 isoforms also explains the elevated extracellular dehydroascorbate (DHA) and reduced intracellular ascorbic acid (Rumsey *et al.*, 1997) related to hyperglycemia as described previously (Ely, 1981). Ely (1981) proposed that reduced intracellular ascorbic acid resulted in decreased hexose monophosphate shunt activity (DeChatelet *et al.*, 1972), which might suppress deoxyribonucleic acid (DNA) synthesis as shown in Figure 1.3. Reduced DNA synthesis may slow cell division, leading to impaired cell proliferation or anomalies. It has also been suggested that elevated extracellular DHA may inhibit mitosis or cell proliferation (Edgar, 1970).

This decrease in intracellular glucose concentration leads to a lower cell number in the ICM, either by increased apoptotic rate (Pampfer *et al.*, 1997b; Moley *et al.*, 1998a), or by diminished proliferation of these cells (Pampfer *et al.*, 1990). Decrease in glucose transport and metabolism is not only related to progressive decrease in embryo viability but served as important regulatory points in the early apoptotic cascade (Johnson *et al.*, 1996; Li *et al.*, 1998; Shim *et al.*, 1998; Bialik *et al.*, 1999, Lin *et al.*, 2000). Maternal hyperglycemia, moreover, can cause direct disruption of the highly regulated gene program that controls the expression pattern of crucial developmental determinants during early embryogenesis, including apoptosis (Phelan *et al.*, 1997; Cai *et al.*, 1998; Moley *et al.*, 1998a; Pampfer *et al.*, 2001).

Three cell death paradigms that are linked to decreased GLUT include, (i) induction of ATP depletion and stimulation of the mitochondrial death cascade or (ii) induction of oxidative stress and triggering of Bax-associated




Figure 1.3 Mechanism of hyperglycemia-induced alterations in cell division and congenital anomalies
(Adapted from Ely, 1981)

events including the c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK) signalling pathways or (iii) regulation of expression of the gene encoding hypoxia-inducible factor 1 α (HIF-1 α) and the stabilization of p53 by HIF-1 α binding, leading to an increase in p53-associated apoptosis and, in turn, increased expression of Bax, and thus exaggerated apoptosis within blastocysts during glucose deprivation (Chi *et al.*, 2000; Moley and Mueckler, 2000; Keim *et al.*, 2001).

The outcome of apoptosis during preimplantation stage will depend on the percentage of cell death, if more than 60% of ICM undergo cell death, the pregnancy may result in fetal loss and resorption. However, the death of fewer cells (e.g. 40-45%) can result in either fetal resorption or malformation if this cell death involves key progenitor cells in development (Tam, 1988; Moley, 2001).

Another possible mechanism of hyperglycemia-induced congenital anomalies that has been put forward is related to dysregulation in the uterine cytokine secretion (Pampfer, 2001). Diabetes-induced modifications in the oviductal and uterine concentrations of nutrients (such as increased glucose levels), hormones (such as decreased insulin levels), growth factors, and cytokines (increased local synthesis of inhibitory factors or decreased local synthesis of stimulatory factors) are likely to elicit alterations in embryo development before implantation and organogenesis.

Studies in STZ- and alloxan-treated diabetic mice exhibit an increased amount of tumour necrosis factor- α (TNF- α) messenger ribonucleic acid

(mRNA) and protein in the uterus and placenta of diabetic mice (Pampfer *et al.*, 1995; Flein *et al.*, 2001) as well as a marked reduction in pregnancy rate and a high incidence of litters with severely malformed fetuses (Torchinsky *et al.*, 1997, Machado *et al.*, 2001). In addition, overexpression and excessive secretion of TNF- α by uterine cells in diabetic pregnancy may induce a decrease in cell number of the ICM as reported in an earlier study (Pampfer *et al.*, 1997b; Wu *et al.*, 1999).

TNF- α acts in a cell type- and stimulus-dependent manner, to generate apoptotic-signalling pathways (Baud and Karin, 2001; Gupta, 2001). The apoptotic action of TNF- α could occur mainly through its binding to the type 1 receptor TNF- α , followed by the activation of caspase 8 (Slee *et al.*, 1999; Mohr *et al.*, 2002; Torchinsky *et al.*, 2003), which is considered to be among the main mediators of apoptosis (Baud and Karin, 2001; Gupta, 2001). The apoptotic action of TNF- α could be mediated through interleukin-1 β (IL-1 β) secreted by macrophages (Pampfer *et al.*, 1999) localized at the subepithelial region of the uterine stroma (Takacs *et al.*, 1988).

The mechanism of hyperglycemia-induced IL-1 β secretion has been proposed to be via the formation and interaction of advanced glycation end products, AGE (Vlassara *et al.*, 1988). Macrophages have a receptor that recognizes the AGE moiety and mediates the uptake and degradation of AGE proteins. This removal process is associated with the production and secretion of TNF- α and IL-1. The localized release and action of these cytokines may play